Ethypharm has drawn a significant USD 3 million investment plan for its Indian operations. The company will be investing USD 2 million to upgrade its existing WHO GMP approved production facility at Ambernath, near Mumbai, to EUGMP standards. The company plans to increase production capacity of its Ambernath facility.
Another USD 1 million will be invested in upgrading the R&D center, also located at Ambernath, to incorporate a Scale up plant of EUGMP / USFDA level, claims a release.
"With plant expansion, we plan to increase production in Ambernath facility from 75 crore/dossiers/annum to 100 crore/dossiers/annum," Ajey Kumar, CEO, Ethypharm told Pharmabiz. Ethypharm LL India is specialised in the Novel Drug Delivery Systems (NDDS).
Globally, the market for NDDS is about $75 billion or about 15 % of total pharmaceutical market. In India however NDDS constitutes not more than 5 % of the total pharmaceutical market and is poised for an explosive growth.